Bennett Julie, Levine Adrian B, Nobre Liana, Negm Logine, Chung Jiil, Fang Karen, Johnson Monique, Komosa Martin, Krumholtz Stacey, Nunes Nuno Miguel, Rana Mansuba, Ryall Scott, Sheth Javal, Siddaway Robert, Bale Tejus A, Bouffet Eric, Cusimano Michael D, Das Sunit, Detsky Jay, Dirks Peter, Karajannis Matthias A, Kongkham Paul, Giantini-Larsen Alexandra, Li Bryan Kincheon, Lim-Fat Mary Jane, Lin Andrew L, Mason Warren P, Miller Alexandra, Perry James R, Sahgal Arjun, Sait Sameer Farouk, Tsang Derek S, Zadeh Gelareh, Laperriere Normand, Nguyen Lananh, Gao Andrew, Keith Julia, Munoz David G, Tabori Uri, Hawkins Cynthia
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Nat Cancer. 2025 May 7. doi: 10.1038/s43018-025-00962-x.
Gliomas are a major cause of cancer-related deaths in adolescents and young adults (AYAs; ages 15-39 years). Different molecular alterations drive gliomas in children and adults, leading to distinct biology and clinical consequences, but the implications of pediatric- versus adult-type alterations in AYAs are unknown. Our population-based analysis of 1,456 clinically and molecularly characterized gliomas in patients aged 0-39 years addresses this gap. Pediatric-type alterations were found in 31% of AYA gliomas and conferred superior outcomes compared to adult-type alterations. AYA low-grade gliomas with specific RAS-MAPK alterations exhibited senescence, tended to arise in different locations and were associated with superior outcomes compared to gliomas in children, suggesting different cellular origins. Hemispheric IDH-mutant, BRAF p.V600E and FGFR-altered gliomas were associated with the risk of malignant transformation, having worse outcomes with increased age. These insights into gliomagenesis may provide a rationale for earlier intervention for certain tumors to disrupt the typical behavior, leading to improved outcomes.
Cochrane Database Syst Rev. 2016-6-27
Curr Neurol Neurosci Rep. 2025-8-12
N Engl J Med. 2023-9-21
Cell Genom. 2023-5-31